Literature DB >> 27308647

Liver Stiffness Evaluation by Transient Elastography in Type 2 Diabetes Mellitus Patients with Ultrasound-proven Steatosis.

Ioan Sporea1, Ruxandra Mare1, Raluca Lupușoru1, Alexandra Sima2, Roxana Sirli3, Alina Popescu1, Romulus Timar2.   

Abstract

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases worldwide. The aim of our study was to evaluate a population of diabetic patients regarding the severity of liver steatosis and liver fibrosis.
METHODS: The study included 392 type 2 diabetic patients prospectively randomized, evaluated in the same session by transabdominal ultrasound to assess steatosis and by liver elastography to assess fibrosis (Transient Elastography - TE, FibroScan, EchoSens). Steatosis severity was graded using a semi-quantitative scale (S0-no steatosis; S1-mild steatosis; S2-moderate steatosis; S3-severe steatosis). For differentiation between stages of liver fibrosis, the following cut-off values were used (Wong et al., 2010): F2-F3: 7-10.2kPa, F4>/=10.3 kPa.
RESULTS: Reliable elastographic measurements were obtained in 76% (298/392) patients. By using the proposed cut-off values, significant fibrosis (F2-F3) was found in 18.8% (56) patients with steatosis, while 13.8% (41) had cirrhosis (F4). Significant fibrosis (F2-F3) was found in 20.4% (20/98) of the patients with S1, in 18.6% (22/118) of those with S2 and in 31.8% (14/44) of those with S3, while cirrhosis (F4) was diagnosed in 7.1% (7/98) patients with S1, in 20.3% (24/118) of those with S2 and in 22.7% (10/44) of those with S3.
CONCLUSIONS: Liver steatosis diagnosed by ultrasound is very frequently found in type 2 diabetes mellitus patients, more than half of them having moderate/severe steatosis. A significant liver stiffness increase was found in more than 30% of these patients. Liver stiffness assessment in type 2 diabetic patients should be performed systematically to identify those with significant liver fibrosis.

Entities:  

Mesh:

Year:  2016        PMID: 27308647     DOI: 10.15403/jgld.2014.1121.252.lsf

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  7 in total

1.  Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study.

Authors:  Meryem Demir; Oğuzhan Deyneli; Yusuf Yılmaz
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

Review 2.  Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.

Authors:  Michelle T Long; Sanil Gandhi; Rohit Loomba
Journal:  Metabolism       Date:  2020-05-05       Impact factor: 8.694

3.  Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years.

Authors:  Jun Chen; Piao Hu; Yanfei Wang; Zhongxin Zhu
Journal:  BMC Endocr Disord       Date:  2022-05-13       Impact factor: 3.263

Review 4.  A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases.

Authors:  Yingying Zhao; Huichun Xing
Journal:  J Diabetes Res       Date:  2017-03-02       Impact factor: 4.011

Review 5.  Non-alcoholic fatty liver disease: an update on diagnosis.

Authors:  Dan L Dumitrascu; Manuela G Neuman
Journal:  Clujul Med       Date:  2018-04-25

6.  Ultrasound Grade of Liver Steatosis Is Independently Associated with the Risk of Metabolic Syndrome.

Authors:  Sanda Mustapic; Sead Ziga; Vladimir Matic; Tomislav Bokun; Bozo Radic; Marko Lucijanic; Srecko Marusic; Zarko Babic; Ivica Grgurevic
Journal:  Can J Gastroenterol Hepatol       Date:  2018-08-23

7.  Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial.

Authors:  Rasha R El-Kady; Amani K Ali; Lamia M El Wakeel; Nagwa A Sabri; May A Shawki
Journal:  Ther Adv Chronic Dis       Date:  2022-02-23       Impact factor: 5.091

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.